Skip to Main Content

Advertisement

Issue Archive

Table of Contents

BLOOD ADVANCES TALK

POINT-COUNTERPOINT

This article has a companion Counterpoint by Poston and Garcia.

This article has a companion Point by Chiasakul and Cuker.

EXCEPTIONAL CASE REPORT

STIMULUS REPORT

CLINICAL TRIALS AND OBSERVATIONS

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

MYELOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

Professional illustration by Patrick Lane, ScEYEnce Studios.

TRANSFUSION MEDICINE

TRANSPLANTATION

  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    A schematic diagram of CLT030 (CLL1-ADC) antibody-drug conjugate (ADC). The D212 linker-payload is the D211 payload with a cleavable Val-Ala linker, PEG-8 spacer, and maleimide functional group to conjugate the linker-payload to reactive thiol groups on the antibody. The D212 linker-payload is conjugated to engineered cysteine residues of anti-CLL1 antibody, resulting in a drug-to-antibody ratio of 2. See the article by Jiang et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement